NG 52

NG 52 (CAS No.: 212779-48-1) is a cell-permeable, orally active small-molecule kinase inhibitor belonging to the purine analog class, widely utilized in biochemical and pharmacological research to interrogate cyclin-dependent kinase-related signaling pathways. It selectively targets the yeast cyclin-dependent kinases Cdc28p and Pho85p by binding to their ATP-binding sites, exhibiting inhibitory activity in the low micromolar range, and also inhibits phosphoglycerate kinase 1 (PGK1), implicating its role in metabolic regulation and cancer cell energetics. NG 52 demonstrates specificity over other kinases such as Kin28p, Srb10, and Cak1p, highlighting its utility for dissecting kinase-selective mechanisms. Functionally, it has been shown to suppress cellular proliferation in various models, including yeast and human glioma cell lines, and to inhibit tumor growth in xenograft models in a dose-dependent manner, supporting its relevance in oncology-focused research. As an analog of known cyclin-dependent kinase inhibitors, NG 52 serves as a valuable chemical probe for studying cell cycle control, kinase-driven signaling networks, and metabolic enzyme modulation, with experimental concentrations or dosing regimens typically optimized according to specific in vitro or in vivo study designs.